设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 288|回复: 0

RNA CARs技术在实体肿瘤中成功运用会面临的障碍

[复制链接]
发表于 2016-1-5 23:49:07 | 显示全部楼层 |阅读模式
Roadblocks to success for RNA CARs in solid tumors.
While CAR therapy has begun to demonstrate efficacy, cell-engineering techniques that result in permanent genomic modification carry several safety concerns. CAR expression driven by RNA creates a platform for delivery of highly-active cell therapy while avoiding long-term CAR-driven toxicity. Using models of pediatric neuroblastoma, we have found that RNA CAR T cell activity is limited by ineffective tumor infiltration.
KEYWORDS:
GD2; Lenti CAR, lentivirally-modified chimeric antigen receptor T cell; RNA; RNA CAR, RNA-modified chimeric antigen receptor T cell; chimeric antigen receptors; pediatrics; solid tumors
RNA CARs技术在实体肿瘤中成功运用会面临的障碍
CAR治疗技术展现了其有效性,细胞修饰技术导致的永久性的基因修饰会产生严重的安全隐患。通过RNA产生CAR,不但能够构建高活性的细胞治疗能力,而且还能够避免长期的CAR导致的毒副作用。通过构建儿童神经细胞瘤的模型,我们发现RNA CAR-T细胞的活性受到无效肿瘤细胞浸润的影响。
关键词: GD2;Lenti CAR;慢病毒载体修饰的嵌合抗原受体T细胞;RNA;RNA CAR;RNA修饰的嵌合抗原受体T细胞;嵌合抗原受体; ;儿科;实体瘤
出自爱康得生物技术

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-1-16 20:51 , Processed in 0.096821 second(s), 20 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表